Universal reference book for medicines
Product name: OROCAMAG ® (OROCAMAG)

Active substance: orotic acid, magnesium salt, orotic acid, potassium salt

Type: A drug that improves the metabolism and energy supply of tissues

Manufacturer: PIK-PHARMA (Russia) manufactured by PIK-PHARMA PRO (Russia)

Composition, form of production and packaging
Capsules hard gelatinous, size No. 0, white or slightly yellowish in color; the contents of the capsules are white powder.
1 caps.

potassium orotate 125 mg

magnesium orotate dihydrate 125 mg

Excipients: silicon colloidal dioxide - 1.5 mg, microcrystalline cellulose - 38.6 mg, magnesium stearate - 0.9 mg, giprolase - 9 mg.

The composition of the capsule shell: gelatin, titanium dioxide.

10 pieces.
- packings cellular planimetric (6) - packs cardboard.
15 pcs.
- packings cellular planimetric (4) - packs cardboard.
60 pcs.
- polymer cans (1) - packs of cardboard.
120 pcs.
- polymer cans (1) - packs of cardboard.

Description of the drug approved by the manufacturer for the printed edition of 2011.


Orotic acid and its salts are involved in the metabolism.
Kalin and magnesium, being important intracellular ions, play a major role in the functioning of many enzymes.
Orotic acid is one of the precursors of pyrimidine nucleotides that are part of nucleic acids, it is also necessary for the synthesis of amino acids;
intermediate uridine products of orotate during the formation of uracil monophosphate stimulate glycolysis, thereby promoting the synthesis of adenosine triphosphate (ATP). Orthoic acid and its salts normalize protein metabolism; enhance tissue repair and regeneration. Also, orotic acid has an anabolic effect; increases the formation of albumins in the liver with prolonged hypoxia, including against a background of chronic heart failure; improves the functional state of the heart. Orotic acid is also necessary for fixing magnesium ions on ATP in the cell and manifesting its action.
Magnesium is the most important macroelement, plays the role of a physiological calcium antagonist, activates more than 300 biochemical reactions as a cofactor of various enzymes, takes part in the process of muscle contraction;
promotes the normal functioning of cardiomyocytes; increases resistance to stress; strengthens the action of cardiotropic, antiarrhythmic and antihypertensive agents. The use of magnesium is indicated in conditions associated with its deficiency.
Potassium is the main intracellular ion, participates in the regulation of the most important functions of the body, has a weak diuretic effect, weakens the arrhythmogenic properties of cardiac glycosides.
Its administration is also necessary if this ion is deficient, including against the background of the use of thiazide diuretics.
Combination of potassium orotate and magnesium orotate in one preparation significantly increases the therapeutic effectiveness of each of the components, since orotic acid acts as a fixer of magnesium and potassium ions, thus enhancing their functions as regulators of biochemical and physiological processes.


Studies on pharmacokinetics have not been conducted.


- ischemic heart disease (stable angina), supraventricular extrasystole (as an additional tool in complex therapy).


Capsules should be taken orally, with a small amount of water.
Apply 4 capsules 3 times a day. The duration of the course of treatment is not less than 4 - 6 weeks.Repeated courses - on the advice of a doctor.

Hyperkalemia (nausea, vomiting, diarrhea, paresthesia), hypermagnia (hyperemia of the face, thirst, bradycardia, lowering blood pressure, muscle weakness, fatigue, paresis, coma, areflexia, respiratory depression, seizures), nausea, vomiting, diarrhea, pain in the epigastric region (in patients with an anatomic gastritis or cholecystitis), it is possible to develop allergic dermatoses.
If any of the side effects listed in the manual are aggravated, or if you notice any other side effects not listed in the instructions, tell your doctor.

- hypersensitivity to the drug;

- acute and chronic renal failure, anuria;

- oliguria;

- urolithiasis (phosphate and magnesium-calcium concretions);

- Hyperkalemia;

- hypermagnesia;

- atrioventricular blockade (I-III degree);

- cardiogenic shock;

metabolic acidosis;

- dehydration;

- hemolysis;

- Myasthenia gravis;

cirrhosis of the liver with ascites;

- age up to 18 years;

- pregnancy and lactation.

Impaired renal function.

The use of the drug Orokamag ® during pregnancy is contraindicated, due to the lack of data on its use during pregnancy.
It is necessary to stop breastfeeding during the period of application of the drug Orokamag ® .

Contraindicated: acute and chronic renal failure, anuria, oliguria, urolithiasis (phosphate and magnesium-calcium concretions).
With caution: impaired renal function.

Contraindicated in cirrhosis of the liver with ascites.


Contraindicated at the age of 18 years.


When used simultaneously with preparations of iron, tetracycline and sodium fluoride, taking Orochamag ® should be delayed for at least 2 hours.

When used simultaneously with potassium preparations, it is recommended to monitor the potassium content in the blood plasma.

If there are signs of diarrhea, the dose of the drug should be reduced.

In some cases, with allergic dermatoses, the drug is canceled, if necessary, antihistamines are used.
A clinical study on the effect on the ability to drive vehicles and engage in certain activities that require increased concentration and speed of psychomotor reactions has not been carried out.

Symptoms: hyperkalemia and hypermagnia.

Treatment: iv calcium chloride;
if necessary, hemodialysis and peritoneal dialysis.

Pharmacodynamic: combined use with potassium-sparing diuretics (triamterene, spironolactone, amiloride), beta adrenoblockers, cyclosporine, heparin, angiotensin converting enzyme (ACE) inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs) increases the risk of gnercalemia up to arrhythmia and asystole.
The use of potassium preparations together with glucocorticosteroids eliminates the hypokalemia caused by the latter. Under the influence of potassium, undesirable effects of cardiac glycosides decrease. Strengthens the negative batmotropnoe action of antiarrhythmics. General anesthetics (agents for general anesthetics) increase the oppressive effect of magnesium preparations on the central nervous system; when used simultaneously with depolarizing muscle relaxants (atrakury bezilat, decamethonium bromide, suxamethonium chloride, bromide, iodide), neuromuscular blockade may be strengthened; calcitriol increases magnesium in the blood plasma, calcium preparations reduce the effect of magnesium preparations.
Pharmacokinetic: astringent and enveloping agents reduce the absorption of the drug in the gastrointestinal tract and it is necessary to observe a three-hour interval between taking Orokamag ® with the listed products.
With simultaneous use with preparations of iron, tetracycline and sodium fluoride, their absorption decreases in the gastrointestinal tract.

The drug is approved for use as a means of OTC.


In a dry, protected from light place at a temperature of no higher than 25 ° C.
Keep out of the reach of children.
Shelf life.
3 years. Do not use after expiry date.
Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y
Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!